{"filing":{"accession_number":"0001193125-26-286780","cik":"0001374690","ticker":"LRMR","company_name":"Larimar Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"lrmr-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526286780/lrmr-20260629.htm"},"events":[{"id":14421,"run_id":12842,"accession_number":"0001193125-26-286780","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Larimar announced submission of the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia, along with positive long-term open-label study data showing sustained skin frataxin (FXN) levels and directional clinical improvements. This is a material regulatory and clinical milestone for a clinical-stage biotech company, but does not fit neatly into the specific event categories (not an earnings release, M\u0026A activity, impairment, or other defined types). The disclosure centers on a significant product development and regulatory advancement that would affect a reasonable investor's assessment of the company's progress toward commercialization.","company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11848,"accession_number":"0001193125-26-286780","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Larimar announced submission of the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia, along with positive long-term open-label study data showing sustained skin frataxin (FXN) levels and directional clinical improvements. This is a material regulatory and clinical milestone for a clinical-stage biotech company, but does not fit neatly into the specific event categories (not an earnings release, M\u0026A activity, impairment, or other defined types). The disclosure centers on a significant product development and regulatory advancement that would affect a reasonable investor's assessment of the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:34:41.516114+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11848,"accession_number":"0001193125-26-286780","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Larimar announced submission of the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia, along with positive long-term open-label study data showing sustained skin frataxin (FXN) levels and directional clinical improvements. This is a material regulatory and clinical milestone for a clinical-stage biotech company, but does not fit neatly into the specific event categories (not an earnings release, M\u0026A activity, impairment, or other defined types). The disclosure centers on a significant product development and regulatory advancement that would affect a reasonable investor's assessment of the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:34:41.516114+00:00","company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","filing_date":"2026-06-29"}]}